Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile

Paused

Conditions studied: Metastatic Triple-Negative Breast Cancer

In brief

Recent progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies including breast cancer. It has been shown that levels of certain cytokines were correlated with increased response to immunotherapy in patients with metastatic breast cancer. In this study investigators will perform cytokine profiling among patients diagnosed with metastatic triple-negative breast cancer at different time points during the treatment.

Key facts

Study ID

NCT04250818

Run by

Texas Tech University Health Sciences Center, El Paso

People needed

20

Starts

2019-07-02

Expected to finish

2021-05-01

Last updated by the study team

2021-05-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of metastatic triple negative breast cancer
• 18 years of age or older

You may not qualify if…

• Younger than 18
• Unwilling to participate or unable to give informed consent

Where it is running

• Texas Tech University HSC El Paso — El Paso, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.